Synapse - Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma Meeting Abstract

Authors:	Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; Schoder, H.; Michaud, L.; Palomba, M. L.; Falchi, L.; Lahoud, O. B.; Hamlin, P. A.; Yahalom, J.; Johnson, W. T.; Zelenetz, A. D.; Intlekofer, A. M.; Owens, C.; Batlevi, C. L.; Hamilton, A.; Caron, P. C.; Horwitz, S. M.; Galasso, N.; Hancock, H.; Davey, T.; Santarosa, A.; Perez, L.; Capadona, C.; Munayirji, B.; Matasar, M. J.; Pongas, G.; Casper, E.; Salles, G.; Moskowitz, C. H.; Vardhana, S.; Moskowitz, A. J.
Abstract Title:	Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	9286
End Page:	9288
Language:	English
ACCESSION:	WOS:000893230302128
DOI:	10.1182/blood-2022-160206
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos